HK1038886B - USE OF α1β1 INTEGRIN RECEPTOR INHIBITORS AND TGF-β1 INHIBITORS FOR THE PREPARATION OF A PHARMACEUTICAL COMPOSITION FOR TREATMENT OF KIDNEY DISORDER - Google Patents

USE OF α1β1 INTEGRIN RECEPTOR INHIBITORS AND TGF-β1 INHIBITORS FOR THE PREPARATION OF A PHARMACEUTICAL COMPOSITION FOR TREATMENT OF KIDNEY DISORDER

Info

Publication number
HK1038886B
HK1038886B HK02100508.3A HK02100508A HK1038886B HK 1038886 B HK1038886 B HK 1038886B HK 02100508 A HK02100508 A HK 02100508A HK 1038886 B HK1038886 B HK 1038886B
Authority
HK
Hong Kong
Prior art keywords
inhibitors
tgf
preparation
treatment
pharmaceutical composition
Prior art date
Application number
HK02100508.3A
Other languages
Chinese (zh)
Other versions
HK1038886A1 (en
Inventor
D‧科斯格羅維
Original Assignee
博伊斯鎮國家研究醫院
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US1999/011073 external-priority patent/WO1999061040A2/en
Application filed by 博伊斯鎮國家研究醫院 filed Critical 博伊斯鎮國家研究醫院
Publication of HK1038886A1 publication Critical patent/HK1038886A1/en
Publication of HK1038886B publication Critical patent/HK1038886B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2842—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta1-subunit-containing molecules, e.g. CD29, CD49
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • C—CHEMISTRY; METALLURGY
    • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
    • C09K3/00—Materials not provided for elsewhere
    • C09K3/18—Materials not provided for elsewhere for application to surfaces to minimize adherence of ice, mist or water thereto; Thawing or antifreeze materials for application to surfaces
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/906—Drug delivery
    • Y10S977/907—Liposome

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Combustion & Propulsion (AREA)
  • Materials Engineering (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK02100508.3A 1998-05-22 2002-01-22 USE OF α1β1 INTEGRIN RECEPTOR INHIBITORS AND TGF-β1 INHIBITORS FOR THE PREPARATION OF A PHARMACEUTICAL COMPOSITION FOR TREATMENT OF KIDNEY DISORDER HK1038886B (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US8658798P 1998-05-22 1998-05-22
US8876698A 1998-06-02 1998-06-02
US15048598A 1998-09-09 1998-09-09
PCT/US1999/011073 WO1999061040A2 (en) 1998-05-22 1999-05-19 USE OF α1β1 INTEGRIN RECEPTOR INHIBITORS AND TGF-β1 INHIBITORS IN THE TREATMENT OF KIDNEY DISEASE

Publications (2)

Publication Number Publication Date
HK1038886A1 HK1038886A1 (en) 2002-04-04
HK1038886B true HK1038886B (en) 2005-09-23

Family

ID=27375439

Family Applications (1)

Application Number Title Priority Date Filing Date
HK02100508.3A HK1038886B (en) 1998-05-22 2002-01-22 USE OF α1β1 INTEGRIN RECEPTOR INHIBITORS AND TGF-β1 INHIBITORS FOR THE PREPARATION OF A PHARMACEUTICAL COMPOSITION FOR TREATMENT OF KIDNEY DISORDER

Country Status (2)

Country Link
KR (1) KR100574597B1 (en)
HK (1) HK1038886B (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA116639C2 (en) * 2012-10-09 2018-04-25 Рег'Юлес Терап'Ютікс Інк. Methods for treatment of alport syndrome

Also Published As

Publication number Publication date
HK1038886A1 (en) 2002-04-04
KR100574597B1 (en) 2006-04-28
KR20010052390A (en) 2001-06-25

Similar Documents

Publication Publication Date Title
HK1076723A1 (en) Highly selective norepinephrine reuptake inhibitors and the use for the preparation of the medicament thereof
HUP0200831A2 (en) Novel pharmaceutical composition containing amoxycillin and its use
NZ513889A (en) Kappa agonist compounds, pharmaceutical formulations and methods of prevention and treatment of pruritus therewith
HUP0202319A2 (en) Use of mek inhibitors for the preparation of pharmaceutical compositions treating chronic pain
HUP0400529A3 (en) Use of chlorpromazine and pentamidine for preparation of pharmaceutical compositions for the treatment of neoplastic disorders
HUP0203588A3 (en) Analgesic pharmaceutical compositions and their use
HUP0004120A3 (en) Use of cgmp-pde5 inhibitors for the preparation of pharmaceutical compositions treating neuropathy
ZA985618B (en) Sulfonamide compounds and pharmaceutical use thereof
EP0858334A4 (en) Analgesic immediate and controlled release pharmaceutical composition
HUP0103558A3 (en) Pharmaceutical composition containing nmda receptor antagonist for the treatment of stroke and traumatic brain insury
IL147503A0 (en) Oxazolidinone compounds and methods of preparation and use thereof
HK1015351A1 (en) Substituted amino compounds and their use as analgesic active substances
IL138888A0 (en) Pharmaceutical composition and combination preparation for immunosuppressive therapy
IL138416A (en) Use of dexmedetomidine or pharmaceutical acceptable salt thereof for preparation of a sedative
HUP0202048A3 (en) Use of alpha1betha1 integrin receptor inhibitors and tgf-betha1 inhibitors in the treatment of kidney disease
PT1202996E (en) TITANIUM COMPOUNDS FOR THEIR PREPARATION AND THEIR USE
HUP0100171A3 (en) Use of endothelin receptor antagonists for producing pharmaceutical preparations for combating obesity
HK1038886B (en) USE OF α1β1 INTEGRIN RECEPTOR INHIBITORS AND TGF-β1 INHIBITORS FOR THE PREPARATION OF A PHARMACEUTICAL COMPOSITION FOR TREATMENT OF KIDNEY DISORDER
HUP9802716A3 (en) Pharmaceutical composition of analgesic activity
EE05317B1 (en) Ethin 1 "Pharmaceutical Composition Containing Stradiol and Drospirenone for Use as a Contraceptive
HUP0203212A3 (en) Integrin inhibitors, process for preparation thereof, their use preparation of pharmaceutical compositions and the compositions
HUP0201629A3 (en) Pharmaceutical complex containing eletriptan and cyclodextrin-derivative, pharmaceutical composition containing it, process for its preparation and its use
HUP0103947A3 (en) Novel methanesulfonate salts of pyridopyrazine compound and crystals thereof and their pharmaceutical use
EP1243609A4 (en) Succinimide compounds and use thereof
ZA98484B (en) Use of beta3-adrenergic receptor agonists for the preparation of healing drugs

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20090519